Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liposome encapsulated prednisolone - Enceladus Pharmaceuticals

Next Previous
X
Search
Drug Profile

Liposome encapsulated prednisolone - Enceladus Pharmaceuticals

Alternative Names: GLPG-0303; Liposomal prednisolone; Nanocort; PEG-liposomal prednisolone sodium phosphate

Latest Information Update: 07 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enceladus Pharmaceuticals
  • Developer Enceladus Pharmaceuticals; Galapagos NV; Leiden University Medical Center; Sun Pharmaceutical Industries; The Rotterdam Eye Hospital
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Glucagon receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase II Arteriovenous fistula; Graves ophthalmopathy; Ulcerative colitis
  • Suspended Multiple sclerosis

Most Recent Events

  • 16 Sep 2020 Liposome encapsulated prednisolone is still in phase II trials for Graves ophthalmopathy in Netherlands (IV) (EudraCT2017-001158-33)
  • 12 Jun 2019 Efficacy and adverse events data from a phase III trial in Rheumatoid arthritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR 2019)
  • 16 Mar 2016 Efficacy and adverse events data from a phase II trial in Ulcerative colitis released by Enceladus Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top